Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933202 · ClinicalTrials.gov registry record
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
A clinical trial, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- 291
- Enrollment target
NCT03933202 is a clinical trial that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 291 participants.
The verdict
NCT03933202 has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- 291 participants
- Enrollment target
Study Summary
To evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with RMS including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS), who transition to cladribine tablets after suboptimal response to any oral or infusion Disease-Modifying Drugs (DMDs) approved in the United States (US) for RMS in a real-world-setting.
Interventions
- DRUG Cladribine Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2024-11-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03933202
The ClinicalTrials.gov registry entry for NCT03933202 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cladribine Tablets is the first listed.
NCT03933202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03933202 about?
NCT03933202 is a clinical study titled "A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)". To evaluate the effectiveness, safety and Patient-Reported Outcomes (PROs) of cladribine tablets in participants with RMS including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS), who transition to cladribine tablets after suboptimal respons...
What is the current status of trial NCT03933202?
This trial is currently completed. The enrollment target is 291 participants. The study started on 2019-07-22. Estimated completion is 2024-11-11.
What interventions are being tested in trial NCT03933202?
The interventions under investigation include: Cladribine Tablets (DRUG).
Who is sponsoring clinical trial NCT03933202?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.